Therapeutics is the process of developing and testing pancreatic cancer treatments, including new drug development, repurposing existing drugs, and targeted therapies. As the driving force behind every major advancement in pancreatic cancer research, the Lustgarten Foundation funds projects that accelerate the development of new therapies. This is accomplished by prioritizing projects that:
- Identify novel drug targets based on the biology of pancreatic cancer initiation and progression.
- Recognize, validate, and clinically test biomarkers for disease monitoring and assessment of clinical response.
- Accelerate preclinical and clinical testing of novel drugs and combinations in pancreatic cancer.
Current pancreatic cancer treatments are non-specific and often induce therapy-limiting side effects. Developing treatments that target the unique features of pancreatic cancer will lead to safer and more effective outcomes.